MassBiologics receives $5 million to fund viral vector manufacturing

MassBiologics viral vector manufacturing grant (press conference highlights)Подробнее

MassBiologics IntroductionПодробнее

Australia's first commercial scale viral vector manufacturing facilityПодробнее

Enabling Large-Scale Production of Viral Vectors in the Gibco™ CTS LV-MAX Lentiviral....Подробнее

Find Your Purpose in Viral Vector ServicesПодробнее

Innovations in viral vector development, scale up and production webinarПодробнее

Non-Viral Vector Design and ProductionПодробнее

Producing Viral Vectors for Clinical Trials With On-Site Clinical Manufacturing FacilityПодробнее

Viral Vector Manufacturing and Analytics (November 30, 2022)Подробнее

Viral vector production series: Technologies for a scalable adenovirus processПодробнее

Viral vector production series: Scale up of viral vector productionПодробнее

[Takara Bio] Viral vector manufacturingПодробнее

Webinar: Standardization and Large-scale Manufacturing of Plasmids for Viral Vector ProductionПодробнее

A Platform Production Process for Manufacturing Viral Vector and Vaccine Therapeutics Using Vero CelПодробнее

Challenges in manufacturing viral vectors for the clinicПодробнее

Viral vector production series: Managing capacity crunchПодробнее

Viral vector production series: Virus propagation challengesПодробнее

KUBio Box for Viral VectorsПодробнее

Viral And Non Viral Vector Manufacturing Market Growth Forecast 2023-2027Подробнее